Jane Chung, R.Ph.

Jane Chung, R.Ph.

Chief Executive OfficeratSutro Biopharma· In proxies 2023–2025

Pay in FY2025+9% from the year before · Sutro Biopharma stock -37.1% the same year

Jane Chung, R.Ph. was paid $1.6M in FY2025 (Dec), up 9%. Sutro Biopharma stock fell 37.1% that year.

Pay$100 in the stock at the end of FY22 → $14
Pay is from the Summary Compensation Table of each Sutro Biopharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Sutro BiopharmaPublic company · 3 yr
    • Chief Executive Officer2023 – Present · 3 yrStock in role -86%
  2. Viracta Therapeutics, Inc.Public company · 2 yr
    • Director2022 – 2024 · 2 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?